Document is current
Any future updates will be listed below
-
Authors
Pavlou, Marina
Schön, Christian
Occelli, Laurence M
Rossi, Axel
Meumann, Nadja
Boyd, Ryan F
Bartoe, Joshua T
Siedlecki, Jakob
Gerhardt, Maximilian J
Babutzka, Sabrina
Bogedein, Jacqueline
Wagner, Johanna E
Priglinger, Siegfried G
Biel, Martin
Petersen‐Jones, Simon M
Büning, Hildegard https://orcid.org/0000-0002-3365-6933
Michalakis, Stylianos https://orcid.org/0000-0001-5092-9238
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SPP2127)
Deutsche Forschungsgemeinschaft (MI 1238/4‐1)
LMU|Center of Integrated Protein Science Munich, Ludwig‐Maximilians‐Universität München
UoC|Center for Molecular Medicine Cologne, University of Cologne
Niedersächsisches Ministerium für Wissenschaft und Kultur
REBIRTH DFG Cluster of Excellence
Myers‐Dunlap Endowment
- License Information
-
More Information
Article History
Received: 3 September 2020
Revised: 14 January 2021
Accepted: 15 January 2021
First Online: 22 February 2021
Conflict of interest
: S.M. and M.B. are co‐founders of the gene therapy company ViGeneron GmbH who owns the rights on the related patent application WO/2019/076856 covering the novel rAAV capsids. All other authors declare no conflict of interest.
